2023
Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease
Higuero Sevilla J, Memon A, Hinchcliff M. Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease. Arthritis Research & Therapy 2023, 25: 118. PMID: 37422652, PMCID: PMC10329300, DOI: 10.1186/s13075-023-03090-y.Peer-Reviewed Original ResearchConceptsConnective tissue disease-associated interstitial lung diseaseInterstitial lung diseaseTreatment of patientsMycophenolate mofetilSSc-ILDLung diseaseClinical trialsScleroderma Lung Study IIPatient-reported outcome instrumentsIdiopathic inflammatory myositisClinical trial resultsInflammatory myositisIntravenous cyclophosphamideOral cyclophosphamideSubcutaneous tocilizumabGood tolerabilityLung functionSystemic sclerosisTreatment armamentariumRheumatoid arthritisPatient outcomesSimilar efficacyOutcome instrumentsPatientsUS FoodCorrection: Learnings from clinical trials in patients with connective tissue disease‑associated interstitial lung disease
Higuero Sevilla J, Memon A, Hinchcliff M. Correction: Learnings from clinical trials in patients with connective tissue disease‑associated interstitial lung disease. Arthritis Research & Therapy 2023, 25: 132. PMID: 37501068, PMCID: PMC10373245, DOI: 10.1186/s13075-023-03123-6.Peer-Reviewed Original ResearchHyperspectral imaging in systemic sclerosis-associated Raynaud phenomenon
Teaw S, Gupta A, Williams A, Wilson F, Sumpio B, Sumpio B, Hinchcliff M. Hyperspectral imaging in systemic sclerosis-associated Raynaud phenomenon. Arthritis Research & Therapy 2023, 25: 10. PMID: 36670487, PMCID: PMC9854186, DOI: 10.1186/s13075-023-02990-3.Peer-Reviewed Original ResearchConceptsRaynaud's condition scoreCochin Hand Function ScaleSSc patientsClinic settingPatient-reported outcome instrumentsResultsNinety-two percentSystemic sclerosis patientsMann-Whitney U testHealthy control participantsCHF scoreSSc durationSSc-RPDigital ulcersCutaneous SScProvocation challengeRaynaud's phenomenonSclerosis patientsClinical trialsOutcome instrumentsOxygen saturationBurden assessmentPatientsCold provocationHemoglobin concentrationDisease severity
2021
Computer vision applied to dual-energy computed tomography images for precise calcinosis cutis quantification in patients with systemic sclerosis
Chandrasekaran AC, Fu Z, Kraniski R, Wilson FP, Teaw S, Cheng M, Wang A, Ren S, Omar IM, Hinchcliff ME. Computer vision applied to dual-energy computed tomography images for precise calcinosis cutis quantification in patients with systemic sclerosis. Arthritis Research & Therapy 2021, 23: 6. PMID: 33407814, PMCID: PMC7788847, DOI: 10.1186/s13075-020-02392-9.Peer-Reviewed Original ResearchConceptsSSc patientsCalcinosis cutisCC lesionsSystemic sclerosisBland-Altman plotsConcordance correlation coefficientIndependent radiologistsLin's concordance correlation coefficientConfidence intervalsValid clinical trialsExpert musculoskeletal radiologistsSpearman correlation coefficientClinical trialsMusculoskeletal radiologistsPatientsBurden quantificationLesionsMean differenceGold standardRadiologistsCorrelation coefficientLonger lengthPhalanxSpearman's rhoValidation study
2020
Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope
Hinchcliff M, O’Reilly S. Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope. Current Rheumatology Reports 2020, 22: 42. PMID: 32562016, PMCID: PMC7305248, DOI: 10.1007/s11926-020-00918-3.Peer-Reviewed Original ResearchConceptsSkin fibrosisNew targetsSSc interstitial lung diseaseAutoimmune connective tissue diseaseSystemic sclerosis therapyConnective tissue diseaseInterstitial lung diseaseCurrent ongoing trialsNew therapeutic targetsActivation of fibroblastsPotential new targetsReviewSystemic sclerosisSclerosis therapyOngoing trialsTissue diseaseLung diseaseClinical trialsTherapeutic targetRate of declineDisease pathogenesisPhase IIIPhase IIFibrosisNew hopeDiseaseHigh-throughput quantitative histology in systemic sclerosis skin disease using computer vision
Correia C, Mawe S, Lofgren S, Marangoni RG, Lee J, Saber R, Aren K, Cheng M, Teaw S, Hoffmann A, Goldberg I, Cowper SE, Khatri P, Hinchcliff M, Mahoney JM. High-throughput quantitative histology in systemic sclerosis skin disease using computer vision. Arthritis Research & Therapy 2020, 22: 48. PMID: 32171325, PMCID: PMC7071594, DOI: 10.1186/s13075-020-2127-0.Peer-Reviewed Original ResearchConceptsSystemic sclerosisFibrosis scoreQuantitative image featuresBiopsy scorePrimary cohortOutcome measuresSecondary cohortDiagnostic scoreSkin severity scoreSSc clinical trialsRodnan skin scoreLogistic regression modelsControl biopsiesRegression modelsSkin scoreSeverity scoreClinical hallmarkClinical trialsForearm biopsiesSSc skinBiopsy sectionsIndependent cohortPatient basisSSc biopsiesCollagen deposition
2019
Complementary therapies for patients with systemic sclerosis
Showalter K, Hoffmann A, DeCredico N, Thakrar A, Arroyo E, Goldberg I, Hinchcliff M. Complementary therapies for patients with systemic sclerosis. Journal Of Scleroderma And Related Disorders 2019, 4: 187-199. PMID: 35382503, PMCID: PMC8922560, DOI: 10.1177/2397198319833503.Peer-Reviewed Original Research
2013
Molecular Signatures in Skin Associated with Clinical Improvement during Mycophenolate Treatment in Systemic Sclerosis
Hinchcliff M, Huang CC, Wood TA, Mahoney J, Martyanov V, Bhattacharyya S, Tamaki Z, Lee J, Carns M, Podlusky S, Sirajuddin A, Shah SJ, Chang RW, Lafyatis R, Varga J, Whitfield ML. Molecular Signatures in Skin Associated with Clinical Improvement during Mycophenolate Treatment in Systemic Sclerosis. Journal Of Investigative Dermatology 2013, 133: 1979-1989. PMID: 23677167, PMCID: PMC3714324, DOI: 10.1038/jid.2013.130.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiopsyCluster AnalysisFemaleGene Expression RegulationGenetic HeterogeneityGenetic MarkersHumansImmunosuppressive AgentsMaleMiddle AgedMycophenolic AcidPredictive Value of TestsReverse Transcriptase Polymerase Chain ReactionScleroderma, SystemicSkin Physiological PhenomenaTranscriptomeYoung AdultConceptsMRSS improvementSystemic sclerosisIntrinsic subsetMycophenolate mofetil treatmentCyclophosphamide-treated patientsGene expression changesGene expression subsetsMycophenolate treatmentTreatment biopsiesClinical improvementMMF treatmentMofetil treatmentGene expression signaturesSSc patientsSerial biopsiesClinical trialsExpression changesBaseline gene expressionGene expressionSSc skinSkin AssociatedPatientsTargeted treatmentPatient biopsiesBiopsy
2007
Obliterative vasculopathy in systemic sclerosis: endothelial precursor cells as novel targets for therapy
Hinchcliff M, Varga J. Obliterative vasculopathy in systemic sclerosis: endothelial precursor cells as novel targets for therapy. Expert Review Of Clinical Immunology 2007, 3: 11-15. PMID: 20476946, DOI: 10.1586/1744666x.3.1.11.Peer-Reviewed Original ResearchSystemic sclerosisObliterative vasculopathyOpen-label clinical trialEfficacy of statinsChronic cardiovascular diseasePrecursor cellsSerious clinical manifestationsEndothelial precursor cellsChronic vasculopathyVascular obliterationClinical manifestationsVascular damageVascular precursor cellsClinical trialsTherapeutic roleCardiovascular diseaseEffective treatmentImpaired productionVasculopathySclerosisNovel targetStatinsDefective vasculogenesisAtorvastatinEndothelial precursors